Trials / Active Not Recruiting
Active Not RecruitingNCT03444844
Biodistribution and Dosimetry of Ga-68 P16-093 in Prostate Cancer
Biodistribution and Dosimetry of Ga-68 P16-093 in Prostate Cancer Patients With Intermediate/High Risk Primary Disease or Biochemical Recurrence After Treatment
- Status
- Active Not Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- Five Eleven Pharma, Inc. · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Initial performance of Ga-68-P16-093 in prostate cancer patients including dosimetry and preliminary efficacy evaluation in BCR patients, and correlation of Ga-68-P16-093 uptake with tissue histopathology in intermediate to high risk primary prostate cancer patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ga-68 P16-093 PET/CT scan | IV injection followed by PET/CT scanning |
Timeline
- Start date
- 2018-05-10
- Primary completion
- 2020-10-27
- Completion
- 2022-07-01
- First posted
- 2018-02-23
- Last updated
- 2022-05-02
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03444844. Inclusion in this directory is not an endorsement.